ResistanceBio is a target and drug discovery platform company focused on identifying novel therapies that overcome treatment-resistant cancer and enable personalized precision medicine. Platform: We’ve developed an in vitro and ex vivo cancer evolution model (the ResCu system®) that maps the cancer resistome by mimicking natural tumor response to treatment. ResCu and patient data combine to create our cancer resistome database. ResCu allows us to exploit novel cancer and immuno-oncology targets through deep learning and biological validation for better therapeutic outcomes for patients.

www.resistance.bio